To read the full post, please click on the title.

Although the critical role of the immune system in cancer has long been recognized, the development of novel oncological pharmacotherapies through specifically targeting the immune system is a relatively new area of research. Key challenges for the effective translation of emerging science ...[read more]

    Friday, 5 May 2017, 11:00AM-12:00PM EDT (UTC -4)

    Modeling and simulation has become an integral and expected part of internal and regulatory decision making, as illustrated by regulatory guidelines and industry best practice guidelines. For example, as a response to a request from the European Medicines Agency (EMA), the...[read more
    Fueled by the pan-cancer genomics landscape and druggable targets discovered in The Cancer Genome Atlas (TCGA), and great successes of clinically actionable pharmacogenetic variants, precision medicine is one of the driving forces for biomedical research. It is becoming...[read more]
    • 15 March 2017
    • Author: Lang Li, PhD
    • Number of views: 321
    • Comments: 0
    Immunotherapy has burst into oncology drug development during recent years by demonstrating some amazing responses in indications earlier associated with a poor prognosis. The immune checkpoint inhibitors act by restoring and stimulating the patient’s own...[read more]
    On Nov 21, 2016, the European Medicines Agency (EMA) hosted a workshop to discuss its draft guideline on qualification and reporting of physiologically-based pharmacokinetic (PBPK) analysis.  The “first-of-its-kind” guideline, published earlier on July 21, 2016, proposes...[read more]
    • 6 January 2017
    • Author: Ping Zhao, PhD
    • Number of views: 1302
    • Comments: 0
    528 N Washington St, Alexandria, VA 22314 |  Ph: 703.836.6981 |